Shingrix Approved in the US for Prevention of Shingles in Immunocompromised Adults

Philadelphia, London -- 26 July 2021 -- GlaxoSmithKline plc today announced that the US Food and Drug Administration (FDA) has approved Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults aged...
Source: - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news

Related Links:

CONCLUSIONS: More than half of the sub-sample reported not knowing about shingles vaccine, therefore, opportunities to increase awareness should be prioritized. Since provider recommendation and flu vaccination receipt had the greatest odds of increasing shingles vaccination, standard practice should include adding shingles to flu vaccine recommendations for age-eligible patients.PMID:34625290 | DOI:10.1016/j.vaccine.2021.09.032
Source: Vaccine - Category: Allergy & Immunology Authors: Source Type: research
Background. Immunization of varicella-zoster virus (VZV)-seronegative solid organ transplant (SOT) patients using the live-attenuated varicella vaccine is generally contraindicated, leaving no widely applicable immunization option. The recombinant subunit herpes zoster vaccine (RZV) is indicated for VZV-seropositive persons to prevent shingles but could potentially also protect VZV-seronegative persons against varicella. We performed a safety and immunogenicity evaluation of RZV in VZV-seronegative SOT recipients as an option for protection. Methods. VZV-seronegative adult SOT patients with no history of varicel...
Source: Transplantation - Category: Transplant Surgery Tags: Original Clinical Science—General Source Type: research
CONCLUSION: This trial informs safety concerns related to use of live virus vaccines in patients receiving biologics.PRIMARY FUNDING SOURCE: The National Institute of Arthritis and Musculoskeletal and Skin Diseases and the American College of Rheumatology.PMID:34570596 | DOI:10.7326/M20-6928
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Source Type: research
J Fam Pract. 2021 Jul;70(6S):S13-S18. doi: 10.12788/jfp.0218.ABSTRACTAt the end of the activity, participants will be able to: • Characterize the burden of herpes zoster infections. • Recommend the recombinant zoster vaccine to patients in accordance with guidance from the Advisory Committee on Immunization Practices. • Implement strategies to increase patient acceptance of herpes zoster and other vaccinations. • Use available resources to increase awareness among patients about the importance and safety of recommended vaccinations.PMID:34432619 | DOI:10.12788/jfp.0218
Source: The Journal of Family Practice - Category: Practice Management Authors: Source Type: research
More News: Drugs & Pharmacology | Food and Drug Administration (FDA) | Herpes | Shingles | Shingles (Herpes Zoster) Vaccine | Vaccines | Varicella-Zoster Virus Vaccine